Literature DB >> 27672055

Is Pelvic Inflammatory Disease a Risk Factor for Ovarian Cancer?

Christina B Rasmussen1, Allan Jensen1, Vanna Albieri2, Klaus K Andersen2, Susanne K Kjaer3,4.   

Abstract

BACKGROUND: Pelvic inflammatory disease (PID) has been proposed as a risk factor for ovarian cancer. However, the existing literature on the association between PID and ovarian cancer risk is inconclusive, and only few cohort studies have been conducted.
METHODS: Using nationwide Danish registries, we conducted a population-based cohort study including all women from the birth cohorts 1940 to 1970 in Denmark during 1978-2012 (n = 1,318,929) to investigate the association between PID and subsequent risk of epithelial ovarian cancer. Among women in the cohort, 81,281 women were diagnosed with PID and 5,356 women developed ovarian cancer during follow-up through 2012. Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the association between PID and ovarian cancer, both overall and according to histotype.
RESULTS: For ovarian cancer overall, we observed no association with PID (HR, 1.05; 95% CI, 0.92-1.20). However, in histotype-specific analyses, we found a statistically significantly increased risk of serous ovarian cancer among women with PID (HR, 1.19; 1.00-1.41; P = 0.047). Conversely, PID was not convincingly associated with risk of any of the other histotypes of ovarian cancer.
CONCLUSIONS: PID was associated with a modestly increased risk of serous ovarian cancer, but not other histotypes. IMPACT: Our results indicate that PID is not a strong risk factor for ovarian cancer. Whether PID is slightly associated with risk of serous ovarian cancer has to be confirmed in other studies. Cancer Epidemiol Biomarkers Prev; 26(1); 104-9. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27672055     DOI: 10.1158/1055-9965.EPI-16-0459

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis.

Authors:  Zhiyi Zhou; Fangfang Zeng; Jianhui Yuan; Jinling Tang; Graham A Colditz; Shelley S Tworoger; Britton Trabert; Xuefen Su
Journal:  Cancer Causes Control       Date:  2017-03-24       Impact factor: 2.506

2.  Association of Powder Use in the Genital Area With Risk of Ovarian Cancer.

Authors:  Katie M O'Brien; Shelley S Tworoger; Holly R Harris; Garnet L Anderson; Clarice R Weinberg; Britton Trabert; Andrew M Kaunitz; Aimee A D'Aloisio; Dale P Sandler; Nicolas Wentzensen
Journal:  JAMA       Date:  2020-01-07       Impact factor: 56.272

Review 3.  Cancer-inducing niche: the force of chronic inflammation.

Authors:  Said M Afify; Ghmkin Hassan; Akimasa Seno; Masaharu Seno
Journal:  Br J Cancer       Date:  2022-03-15       Impact factor: 9.075

Review 4.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

5.  Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.

Authors:  Lixing Chen; Yali Zhai; Yisheng Wang; Eric R Fearon; Gabriel Núñez; Naohiro Inohara; Kathleen R Cho
Journal:  Cancer Res       Date:  2021-04-16       Impact factor: 12.701

6.  LINC00115 promotes stemness and inhibits apoptosis of ovarian cancer stem cells by upregulating SOX9 and inhibiting the Wnt/β-catenin pathway through competitively binding to microRNA-30a.

Authors:  Rui Hou; Luo Jiang
Journal:  Cancer Cell Int       Date:  2021-07-08       Impact factor: 5.722

7.  Association of pelvic inflammatory disease (PID) with ovarian cancer: a nationwide population-based retrospective cohort study from Taiwan.

Authors:  Cherry Yin-Yi Chang; Kent Yu-Hsien Lin; Chien-Chu Huang; Wu-Chou Lin
Journal:  BMC Womens Health       Date:  2021-07-28       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.